Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of GlaxoSmithKline Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix or Rotarix Liquid Formulation (Oral Suspension or Prefilled Syringe) When Administered According to the Prescribing Information in Korea

NCT00750893 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00750893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00750893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of GlaxoSmithKline Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix or Rotarix Liquid Formulation (Oral Suspension or Prefilled Syringe) When Administered According to the Prescribing Information in Korea
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
September 2, 2008
Completion date
June 15, 2013
Enrollment
3,111 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infections, rotavirus